1. ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy. (4th December 2017) Authors: Ross, Jeffrey S.; Ali, Siraj M.; Fasan, Omotayo; Block, Jared; Pal, Sumanta; Elvin, Julia A.; Schrock, Alexa B.; Suh, James; Nozad, Sahar; Kim, Sungeun; Jeong Lee, Hwa; Sheehan, Christine E.; Jones, David M.; Vergilio, Jo‐Anne; Ramkissoon, Shakti; Severson, Eric; Daniel, Sugganth; Fabrizio, David... Journal: Oncologist Issue: Volume 22:Number 12(2017) Page Start: 1444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Author Correction: Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. (25th October 2018) Authors: Whyte, Warren; Bilodeau, Steve; Orlando, David; Hoke, Heather; Frampton, Garrett; Foster, Charles; Cowley, Shaun; Young, Richard Journal: Nature Issue: Volume 562:Number 7728(2018) Page Start: E24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD‐L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. (14th September 2020) Authors: Huang, Richard S.P.; Li, Xinyan; Haberberger, James; Sokol, Ethan; Severson, Eric; Duncan, Daniel L.; Hemmerich, Amanda; Edgerly, Claire; Williams, Erik; Elvin, Julia; Vergilio, Jo‐Anne; Killian, Jonathan Keith; Lin, Douglas; Hiemenz, Matthew; Xiao, Jinpeng; McEwan, Deborah; Holmes, Oliver; Danzi... Journal: Oncologist Issue: Volume 25:Number 11(2020) Page Start: 943 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. (5th May 2016) Authors: Suh, James H.; Johnson, Adrienne; Albacker, Lee; Wang, Kai; Chmielecki, Juliann; Frampton, Garrett; Gay, Laurie; Elvin, Julia A.; Vergilio, Jo-Anne; Ali, Siraj; Miller, Vincent A.; Stephens, Philip J.; Ross, Jeffrey S. Journal: Oncologist Issue: Volume 21:Number 6(2016) Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism‐Driven Clinical Trials. (5th May 2016) Authors: Suh, James H.; Johnson, Adrienne; Albacker, Lee; Wang, Kai; Chmielecki, Juliann; Frampton, Garrett; Gay, Laurie; Elvin, Julia A.; Vergilio, Jo‐Anne; Ali, Siraj; Miller, Vincent A.; Stephens, Philip J.; Ross, Jeffrey S. Journal: Oncologist Issue: Volume 21:Number 6(2016) Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti–Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. (20th January 2022) Authors: Zhang, Liangliang; Hamdani, Omar; Gjoerup, Ole; Cho-Phan, Cheryl; Snider, Jeremy; Castellanos, Emily; Nimeiri, Halla; Frampton, Garrett; Venstrom, Jeffrey M.; Oxnard, Geoffrey; Klempner, Samuel J.; Schrock, Alexa B. Journal: JCO precision oncology Issue: Volume 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. (4th March 2018) Authors: Goodman, Aaron M.; Kato, Shumei; Cohen, Philip R.; Boichard, Amélie; Frampton, Garrett; Miller, Vincent; Stephens, Philip J.; Daniels, Gregory A.; Kurzrock, Razelle Journal: Oncoimmunology Issue: Volume 7:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. Issue 5 (10th May 2021) Authors: Huang, Richard S.P.; Murugesan, Karthikeyan; Montesion, Meagan; Pavlick, Dean C.; Mata, Douglas A.; Hiemenz, Matthew C.; Decker, Brennan; Frampton, Garrett; Albacker, Lee A.; Ross, Jeffrey S. Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Issue 7 (16th January 2018) Authors: Ross, Jeffrey S.; Fakih, Marwan; Ali, Siraj M.; Elvin, Julia A.; Schrock, Alexa B.; Suh, James; Vergilio, Jo‐Anne; Ramkissoon, Shakti; Severson, Eric; Daniel, Sugganth; Fabrizio, David; Frampton, Garrett; Sun, James; Miller, Vincent A.; Stephens, Philip J.; Gay, Laurie M. Journal: Cancer Issue: Volume 124:Issue 7(2018) Page Start: 1358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. (2nd October 2019) Authors: Klempner, Samuel J.; Fabrizio, David; Bane, Shalmali; Reinhart, Marcia; Peoples, Tim; Ali, Siraj M.; Sokol, Ethan S.; Frampton, Garrett; Schrock, Alexa B.; Anhorn, Rachel; Reddy, Prasanth Journal: Oncologist Issue: Volume 25:Number 1(2020) Page Start: e147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗